晶华微(688130) - 2025 Q4 - 年度业绩预告

Financial Projections - The company expects to achieve operating revenue of between 170 million and 180 million yuan in 2025, representing a year-on-year growth of 26.07% to 33.49%[3] - The projected net loss attributable to the parent company for 2025 is estimated to be between 55 million and 30 million yuan, an increase in loss of 19.73 million to 44.73 million yuan compared to the previous year, reflecting a year-on-year increase in loss of 192.11% to 435.54%[3] - The company anticipates a net loss of between 98 million and 70 million yuan after deducting non-recurring gains and losses, which is an increase in loss of 42.24 million to 70.24 million yuan year-on-year, indicating a year-on-year increase in loss of 152.15% to 253.02%[3] - In 2024, the company achieved operating revenue of 134.85 million yuan, with a net loss of 10.27 million yuan attributable to the parent company[4] Acquisitions and Investments - The company acquired 100% equity of Shenzhen Jinghua Zhixin Microelectronics Co., Ltd. for 200 million yuan, with 60 million yuan being conditional payment based on performance targets[5] - The company has increased its R&D expenses to approximately 97 million yuan in 2025, a year-on-year increase of about 33%, with the number of chip projects under research growing by approximately 37%[6] Product Development and Sales - The company successfully introduced new products such as blood glucose meter chips and pressure/temperature sensor chips, leading to improved quarterly sales performance[6] - The company is focusing on resource integration, new product promotion, and cost control to enhance operational efficiency and profitability[6] Regulatory and Compliance Issues - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[7] - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the audited annual report for 2025[8]